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 Abstract  
    
There are still many question open to completely understand the structure-activity 
relationships of G-protein coupled receptors. Issues like the actual mapping of the binding 
site of different subtypes, as well as the mechanism of activation are poorly understood 
[1]. Accordingly, further studies on the structure-activity relationships are necessary. In 
this regard, only a few 3D structures are available from X-ray diffraction studies. 
Computational studies can complement this information through the construction of 
reliable 3D models.  
The goal of the present work is to evaluate the effect of using different ligands to obtain 
reliable models of the three-dimensional structure of a G-protein coupled receptor using 
a specific template. Specifically, we have constructed in the present work a three 
dimensional model of the M3 muscarinic receptor by homology modelling, using the X-
ray structure of M2 muscarinic acetylcholine receptor as template and the sequence 
analyses of muscarinic acetylcholine receptor family. Furthermore, we have studied the 
effect of the ligand used in the modelling process. For this purpose three models of the 
receptor were built, including one without ligand and two models with the selective 
antagonists tiotropium and N-Methylscopolamine, respectively docked into the 
orthosteric binding site.   
The constructed models were refined using molecular dynamic calculations to analyze 
the effect of ligand refinement process and to derive significant conformational 
information. Based on the analysis of the refined models done through the calculations of 
RMSD, RMSF, visualization of the structures and comparison between the refined 
models and the crystal structure of M3 muscarinic receptor, the addition of a ligand in 
construction of homology model (and the subsequent refinement process) stabilize the 
structure. Furthermore, the similarities in the structure conformations of both refined 
models of M3 muscarinic-ligand complexes and the crystal structure of the M3 
muscarinic receptors, suggest that the methodology used in this study can be used in 
prediction of 3D structure prediction GPCR in the absence of crystal structures.  
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 1.0. Introduction  
  
The goal of the present master’s thesis is to evaluate the effect of using different ligands 
to obtain a reliable model of the three-dimensional structure of a G-protein coupled 
receptor using a specific template.  
Our approach to obtain reliable 3D models of G-protein coupled receptors (GPCRs) 
consists of constructing an initial model based on a template, selected from one of the 
solved crystal structures as close as the receptor being modelled and then, being refined 
using molecular dynamics. However, this approach presents several questions that 
requires a deep study: length of the simulations, choice of the template and the use of a 
ligand or not during the refinement process.  
In the present work we have analyzed the effect of the ligand in the modelling of the M3 
muscarinic receptor using the M2 muscarinic receptor as template. Three models were 
constructed and compared to the M3 crystal structure: a model with no ligand inside, 
together with two models using two different antagonists, tiotropium and N-
methylscoplamine.  
1.1. G-protein coupled receptors superfamily  
GPCRs constitute a large family of integral proteins that are activated by foreign 
molecules or other stimuli, binding to the outside region of the cell triggering a signal 
transduction pathway inside the cell that finally produces a cellular response. These 
receptors are embedded in the cell membrane and exhibit a conserved seven 
transmembrane helix bundle structure connected by three extracellular and three 
intracellular loops with the N-terminus located at the extracellular domain.  
This family of receptors -the largest family of integral proteins- contains about 8200 
membranes and are expressed by roughly 3% of genes in the human genome [2]. They 
regulate virtually all known physiological process in mammals and humans, being also 
found in prokaryotic cells, including yeast or choanoflagellates [3].   
GPCRs play an important role in many diseases and, also are the target of approximately 
60% of all modern medicinal drugs [4-9], which contrasts to the small proportion of genes 
in the human genome that are predicted to encode GPCRs, illustrating the importance of 
these proteins both medically and pharmaceutically. They are implicated in a number of 
illnesses on the human genomes, as some studies shows, vast number of mutations have 
 been identified in GPCRs (both activating and inactivating) which are responsible for 
more than 30 different human diseases [10], such as cancer [11, 12], diabetes [13], 
hyperthyroidism [14], ovarian hyper stimulation syndrome [15, 16], congenital stationary 
night blindness [17] as well as being implicated in causing obesity [18].  
Activation of GPCRs can activate different transduction mechanisms, including control 
of enzyme activity, activation of ion channels or vesicle transport, responding to the wide 
range of different stimuli, such as sensory signals, hormones and neurotransmitters. There 
are many ligands that bind to this kind of receptors and active them to provoke different 
physiological responses. Ligands include light-sensitive compounds, odors, pheromones, 
hormones, and neurotransmitters and are different in size and dimension from small 
molecules to peptides and finally large proteins.  
Upon binding of an agonist GPCRs change conformation (in actuality the population of 
the activated conformation increases) allowing the interaction with a heterotrimeric G 
protein, consisting of three distinct subunits, termed α, β and γ. The interaction of agonist 
activated receptor with the G protein receptor provokes a dissociation or at list loss of 
association of the α subunit from the β, γ subunit dimer, that permits that both the α 
subunit and the β, γ subunit can independently activate different downstream signaling 
proteins.  
To further understand the molecular mechanism underlying diseases and the syndromes 
caused by mutations related with these receptors, as well as for the design of small 
molecules acting as therapeutic treatments, a deeper understanding of the structure 
activity relationships is necessary.  
Currently, there is an enormous activity in obtaining three dimensional structures of  
GPCRs from X-ray diffraction studies. This is in part due to the pioneering efforts of 
Kobilka and Leftkowitz devoted to study the structure and function of these proteins, 
considered by the Nobel committee as "crucial for understanding how G-protein– coupled 
receptors function” [19] who awarded them with the Nobel Prize in chemistry of 2012 
for their studies.  
Although there are a number of structures available, including rhodopsin [20, 21], β-1 
adrenergic receptor [22], β-2 adrenergic receptor [4, 23], adenosine A2a receptor [24] and 
others released more recently, computational methods are frequently used to facilitate the 
identification and characterization of novel receptors and their structures. Nowadays 
 computational methods are seems to be most powerful methods when combined with 
high-throughput testing of rationally designed molecules and experimental data in the 
laboratories.  
1.1.1. Classification of the GPCR superfamily  
Although all GPCRs belong to one superfamily, sequence alignments of GPCRs show 
that identity is not overall, but concentrated in the segments related to the transmembrane 
regions. On the basis of these alignments, several conserved residues in the 7TM bundle 
were identified. Moreover, analysis of the alignments show that GPCRs can be 
subdivided into families on the basis sequence homology and/or pharmacological 
characteristics as can be seen in figure (1.1). Families can be classified according to their 
receptor-ligand interactions.  
• Class A (or 1) (Rhodopsin-like)  
• Class B (or 2) (Secretin receptor family)  
• Class C (or 3) (Metabotropic glutamate/pheromone)  
• Class D (or 4) (Fungal mating pheromone receptors)  
• Class E (or 5) (Cyclic AMP receptors)  
• Class F (or 6) (Frizzled/Smoothened) [25-28]  
 
   
Figure (1.1): Classification scheme of GPCRs. Class A (Rhodopsin like), Class B (Secretin like), 
Class C (Glutamate Receptor like), Others (Adhesion), Frizzled, Taste typ-2, unclassified [29]  
The largest family in this classification is rhodopsin like (family A), which give 
importance to this particular membrane of GPCRs.  
1.1.2. 3D structure of GPCRs belonging to the Family A  
As mentioned above all members of the GPCR family exhibit similar features in their 
three-dimensional structure, consisting of a tightly packed bundle of seven 
transmembrane helices. The seven-membrane spanning domain putatively form a barrel 
oriented roughly perpendicular to the plane of the membrane, with an extracellular amino-
terminus and intracellular carboxyl terminus, three connecting loops located in the 
extracellular space (ECL1-ECL2) and three located in the intracellular (see figure (1.2)).  
The extracellular parts of the receptor can be glycosylated. These extracellular loops in 
the family A receptors often contain two highly-conserved cysteine residues that form a 
disulfide bond to stabilize the receptor structure [30, 31].  
   
Figure (1.2): Homology model of the M1 mAchRs. (A) View from the extracellular side (e); (B) 
view from the intracellular side (i); (C) view from the TM domain [30]  
However, despite numerous efforts only few proteins structure has been solved though 
X-ray diffraction studies. Rhodopsin was the first GPCR to be crystallized [32] and its 
structure was deduced from X-ray diffraction data at 2.65 Å resolution (PDB entry 
1GZM). This milestone permitted an unprecedented advance in our understanding of the 
structure and activation of the family A of GPCRs. A few years later, the high resolution 
crystal structure of the β2 adrenergic receptor at 3.4 Å resolution was determined [33, 
34]. This structure provided the opportunity to evaluate an actual ligand-mediated GPCR 
for its use in structure-based drug design. Moreover, the crystal structure of the human 
A2R adenosine receptor, in complex with a high-affinity subtype-selective antagonist, 
ZM241385 at 2.6 Å resolution was also determined [24]. Interestingly, four disulphide 
bridges in the extracellular domain, combined with a subtle repacking of the 
transmembrane helices relative to the adrenergic and rhodopsin structures were detected; 
defining a pocket distinct from that of other structurally determined GPCRs. More 
recently, the crystal structure of the CXCR4 chemokine receptor was published providing 
new insights of the structure of GPCRs. Other structures followed, including the M2 and 
M3 muscarinic acetylcholine receptors, which are members of the subfamily of 
muscarinic receptors (see part (1.2), β-1 adrenergic receptor, opioid receptor, histamine 
receptor and dopamine receptors.  
 1.2. Muscarinic receptors  
The muscarinic acetylcholine receptors belong to the prototypic family A (rhodopsin like) 
GPCRs. Muscarinic acetylcholine receptors have many roles in activity of the 
neurotransmitter acetylcholine in the central and peripheral nervous systems. 
Depolarization of the nerve terminal causes an influx of calcium into the nerve terminal 
and evokes the release of acetylcholine into the synaptic cleft. Acetylcholine is 
synthesized in the cytoplasm of nerve terminals by the enzyme choline acetyltransferase, 
and is then transported into synaptic vesicle.  
As can be seen in figure (1.3), acetylcholine acts at neuron-neuron and neuron-muscular 
cell synapses and binds to the cholinergic receptors: nicotinic and muscarinic, propose by 
Dale in 1914[35]. The former are Na+ and K+ channels, whereas the latter are GPCRs.  
  
Figure (1.3): Action of acetylcholine at the muscarinic receptors, adapted from reference [35]  
  
  
1.2.1. Common structural features of the muscarinic acetylcholine receptors  
Muscarinic receptors like the rest of the members of the family A of GPCRs, exhibit a 
seven helix bundle with a ligand-recognition site which bind to small molecules. The first 
3D structures of these receptors were constructed by homology modelling studies using 
the crystal structure of rhodopsin as template [36]. The main features of muscarinic 
receptor structure are included at table (1.1). The cytoplasmatic domains appear to contain 
important determinants for receptor/G protein interaction and are likely to contain sites 
agonist- and/or second messenger-dependent phosphorylation. Specifically, the third 
intracellular loop (i3) of GPCRs which confers specificity for G protein coupling [37]. In 
 muscarinic receptors as well as dopamine D2–4, adrenergic α2A–2C, and 5-
hydroxytryptamine1A receptors, the i3 has been observed to be long (with more than 100 
residues). In fact the number of residues in muscarinic subtype i3 is between of 160 and 
240 residues.  
  
 Studies based on mutagenesis have shown that the N- and C-terminal portions of i3 play 
a key role in the specificity of the coupling of muscarinic receptors to G proteins. On the 
other hand, most of the central part of i3 can be deleted without impairing the ability of 
the M2 receptor to couple with G proteins, indicating that only the N- and C terminal 
portions of i3 are required for the interaction. Consistently, most GPCRs have a short i3 
and lack its long central part. The question is raised if these long i3 loops have a common 
physiological function and similar tertiary structure, although their sequences are not 
similar [38, 39].  
  
Table (1.1): Main feature of muscarinic acetylcholine receptors  
NUMBERS  FEATURES  
1  The transmembrane segments are likely alpha helices  
2  The ligand recognition site is within the outer half of the membrane 
embedded part of the protein [40].  
3  There are two conserved cysteine residues that form disulfide bound 
between the first and the third extracellular loops [41].  
4  There is a conserved triplet of amino acids (DRY) at the cytoplasmic 
interface of TM3 with the second intracellular, which is important for 
both the expression and function of the receptor [42]. 
  
5  The carboxy-terminus is on the intracellular side of the membrane 
because antibodies to the C-terminus sequences recognize cell-surface 
receptors only when cells are permeabilized [42].  
There is little known about the role of the extracellular receptor domains in the function 
of class A GPCRs that are activated by small diffusible ligands. In the case of the 
muscarinic receptors, the extracellular domains, specially the o2 loop, have been shown 
to play important roles in the binding of certain snake toxins which prevent the receptor 
activation by classic muscarinic agonists. Moreover, despite mutagenesis studies are not 
related to this study, but carry out mutagenesis study with different muscarinic receptor 
subtypes suggests that residues located within the o2 loop and other extracellular domains 
make critical contacts with allosteric muscarinic ligands [43].  
 In addition, recognition of common features of the muscarinic receptors, identifying 
difference among of muscarinic receptors subtypes is important for our study, since 
activation of the various subtypes of muscarinic acetylcholine receptors leads to different 
impacts on some parts of human body. Also, it cause to make better structure design by 
comparison with previous studies.  
1.2.2. Muscarinic receptor subtypes  
There are different subtypes of muscarinic acetylcholine receptors, characterized for 
binding specific ligands. Five subtypes of muscarinic acetylcholine receptors (M1-M5) 
have been recognized and discovered to be widely expressed in the central nervous 
system and in the peripheral tissues. In the CNS, there is evidence that muscarinic 
receptors are involved in motor control, temperature regulation, cardiovascular 
regulation, and memory [40]. They expose high sequence homology with each other and 
with other GPCRs with their seven transmembrane helices, whereas the sequences are 
more variable at the amino terminal extracellular region, lying at the entrance of ligand, 
and at the third intracellular loop. Specifically, the carboxyl-terminal end of the third 
intracellular loop of the receptor has been implicated in the specificity of G protein 
coupling.  Activation of the different subtypes of muscarinic acetylcholine receptors leads 
to different effects, thus for example: M1, M3 and M5 receptors stimulate 
phosphoinositol metabolism, while M2 and M4 receptors inhibit adenylatecyclase 
pathway [44].  
Cloning of the five mammalian genes encoding the muscarinic receptors, was carried out 
by Ishii and Kurachi in 2006 [45]. The expression of different subtypes in cell lines 
resulted in the generation of useful information about their structure-function 
relationships. Their result which are shown in the Table below, illustrate that there are 
many agonists and antagonists for the muscarinic receptors. Some of them are selective 
for certain receptor subtypes and are often used as pharmacological tools for analyzing 
and explaining the function of the individual muscarinic acetylcholine receptors:  
 
 
 
 
 
 
 Table 1.2. Muscarinic receptor subtypes and their pharmacology [45].  
  M1R  M2R  M3R  M4R  M5R  
Non selective 
agonists  
Acetylcholine (muscarinic and nicotinic), Carbachol (muscarinic and nicotinic), 
Muscarine (muscarinic receptor specific), Pilocarpine (muscarinic receptor 
specific), Oxotremorine-M (muscarinic receptor specific), Metoclopradime 
(muscarinic receptor specific), Bethanechol (muscarinic receptor specific)  
Non selective 
antagonists  
Atropine, Scopolamine, QNB (Quinuclidinyl- α-hydroxydiphenylacetate)  
Subtype 
selective 
agonist  
McN-A-343  
l-689,660 
Xanomeline  
CDD-0097  
-  L-689,660  -  -  
Subtype 
selective 
antagonist  
Pirenzepine  
Telenzepine  
MT7  
AF-DX-116  
AF-DX-384  
Methoctramine  
Himbacine  
Tripitramine  
4-DAMP  
Darifenacin  
  
AF-DX-384  
Tropicamide  
Himbacine  
  
 
Here, the M2 muscarinic receptor was chosen among different subtypes. As can see in 
table (1.2), one of the selective M2 muscarinic receptor antagonist is tiotropium, which 
is separated slowly from M3 muscarinic receptor in comparison with M2 muscarinic 
receptor (in part 1.4.1 we will discuss more about tiotropium).  
1.2.3. The M2 muscarinic receptors  
M2 muscarinic receptor is expressed through the central nervous system and in the 
periphery, in particular in smooth muscle and tissues of the heart. The M2 muscarinic 
receptors are responsible of the regulation of force and rate of heart beating. The M2 
receptor appears to be exclusively responsible for these effects on heart beating regulation 
despite the presence of the other muscarinic receptor subtypes in heart cardiac muscle 
[40]. The muscarinic agonist carbachol induces bradycardia in spontaneously beating 
sinoatrial node cells and atria; an effect that was completely abolished in M2 receptor 
deficient mice, indicating that this receptor is responsible for cholinergic deceleration of 
the beating heart. This result was demonstrated through some related exams in M2 
receptor-deficient mice. It is has been also demonstrated that the receptor plays a crucial 
role in muscarinic agonist-induced amnesia [46]. On the other hand, electrophysiological 
examination showed that the muscarinic receptor dependent inhibition of the neuronal (N 
and P/Q type) calcium channel was abolished in sympathetic ganglion neurons from M2 
receptor-deficient mice. In these mice, the carbachol-mediated contraction of a smooth 
muscle preparation was slightly attenuated [47].  
 1.2.4. The M3 muscarinic receptor  
Within the muscarinic family, the M3 subtype mediates many important physiological 
functions, including smooth muscle contraction and glandular secretion. The muscarinic 
M3 receptor is settled mainly in smooth muscles and salivary glands. Therefore, the M3 
selective antagonists have therapeutic potential in the disorders therapy deal with altered 
smooth muscle contractility or tone, including chronic obstructive airway disease, urinary 
incontinence, and irritable bowel syndrome [48-53]. The M3 receptor is found in high 
levels in neuronal cells of the CNS; its distribution largely overlaps with that of m1 and 
m4 subtypes. It is also found in peripheral ganglia, exocrine glands, Smooth muscle, 
vascular endothelium, and in cell lines. No selective agonist has been described [54]. 
Recently, the role of the M3 receptor in insulin secretion was emphasized [55].  
Expression of M3 muscarinic receptor is found in different part of body such as brain 
(smaller expression than M2 and M1 muscarinic receptor), smooth muscle and glandular 
tissue [56]. Central M3 receptors have also been implicated in the regulation of food 
intake, learning and memory, and the proper development of the anterior pituitary gland 
Selective drugs targeted at this receptor subtype may prove clinically useful.  
Knock-out mice lacking the M3 muscarinic receptor exhibit a remarkable (~25%) 
reduction in body weight as well as a significant reduction (~40-95%) in 
carbacholinduced contraction of smooth muscle (urinary bladder, ileum, stomach fundus, 
trachea and gallbladder). Moreover, these mice show no carbachol induced contraction 
of smooth muscle in urinary bladder, in contrast of the effect on the M2 muscarinic 
receptor-knockout mice, suggesting the crucial role of the M3 receptor for inducing 
contraction in this tissue [57].  
Clearly, the M3 muscarinic receptor subtype performs multiple physiological actions and 
it is implicated in numerous pathological conditions. Because of the significant role of 
the M3 receptor in different diseases, it is the main subtype that its structure is 
investigated (figure 1.4)  
   
Figure (1.4): Secondary structure of human M3 muscarinic receptor. In blue the N 
methylglycosilation of the N-terminus, in yellow the cysteine bridge between Cys 141- Cys 221, 
in red, purple and green the residues of the binding pocket. In the C-terminus, it is shown a box 
with nine residues (in blue) corresponding to the C terminal epitope of bovine rhodopsin that is 
recognized by the monoclonal antibody 1D4 [58].  
  
1.2.4.1. Important residues of the M3 muscarinic receptor involved in the interaction with 
ligands  
3D models of receptors are useful to understand the structure–activity relationship (SAR) 
[59, 60]. SAR analysis enables the determination of the chemical groups responsible for 
evoking a target biological effect in the organism. This allows modification of the effect 
or the potency of a bioactive compound (typically a drug) by changing its chemical 
structure. Medicinal chemists use the techniques of chemical synthesis to insert new 
chemical groups into the biomedical compound and test the modifications for their 
biological effects [25].  
Besides a quaternary or protonated amine head group, all strong muscarinic agonists and 
antagonists consist of one or more polar functional groups such as ester, ether or amide 
moieties that are capable of participating in hydrogen bonding interactions [61].  
Based on the this fact that an asparagine residue present in transmembrane domain I of 
all muscarinic receptors is critically involved in the binding of the acetylcholine ester 
moiety by means of hydrogen bonding. Bluml et al. [58] designed several mutants of the 
M3 muscarinic receptor in which residue Asn507 was replaced with alanine, serine, or 
aspartic acid. Their data suggest that the asparagine residue present in transmembrane 
domain VI of all muscarinic receptors is not critical for acetylcholine binding and agonist-
induced receptor activation, but plays a key role in the binding of certain subclasses of 
muscarinic antagonists [62].  
 Mutagenesis as well as peptide labeling and sequencing studies of adrenergic [63-65] and 
muscarinic receptors also suggest that the binding of agonists and antagonists is initiated 
by an ion -ion interaction between the amine moiety of the ligands and an Aspartic acid 
residue located in TM3 of the receptor proteins. Since this residue is conserved among 
all receptors which bind biogenic amine ligands such as the adrenergic, dopamine, 
serotonin, muscarinic and histamine receptors, the specific binding of a particular amine 
ligand to a given receptor must be accomplished by additional mechanisms such as 
hydrogen bonding interactions.  
Conspicuously, the hydrophobic core of all muscarinic receptors contains a series of 
conserved serine, threonine and tyrosine residues which with very few exceptions, do not 
occur in any other G-protein linked receptor. In order to test their potential involvement 
in specific binding of muscarinic ligands, Wess et al. [37] mutated these residues by 
alanine in the case of serine and threonine or by phenylalanine in the case of tyrosine, 
using the rat M3 muscarinic receptor. Ligand binding and functional properties of the 
various mutant receptors were determined after their transient expression in COS7 cells. 
Interestingly, six amino acid residues were identified which appear to be critical for 
agonist binding but are of little or no importance for antagonist binding. Results show 
that among them the mutant M3 muscarinic receptors which showed the strongest 
decreases in agonist binding affinities (30- to 40-fold lower than the wild-type receptor) 
were Thr234Ala and Tyr506Phe. The hydrogen bonding interactions between Thr234 and 
Tyr506 and muscarinic agonists may therefore cause conformational changes in these two 
transmembrane domains which could be transmitted to the connecting loop resulting in 
the activation of specific G proteins [66].  
Despite the muscarinic M3 receptor has been widely studied, the binding mode of the 
ligands is still ambiguous [67]. Until now, various agonists and antagonists of the 
muscarinic M3 receptor have been disclosed, but most of them show little selectivity for 
the M3 receptor. To design selective and potent M3 ligands as potential candidates for 
clinical trials, computational methods are currently used. The present work investigates 
the interactions of human muscarinic M3 receptor and its ligands by means of a combined 
ligand-based and target based approach, consisting of homology modeling of the hM3 
receptor and docking of representative ligands such as tiotropium and NMS. Interactions 
of antagonist with M3 muscarinic receptor occurs in orthosteric binding site which is 
described in next part.  
 1.3. The orthosteric binding site of GPCRs  
Binding of agonists and competitive antagonists to GPCRs occurs at the orthosteric site, 
a hydrophobic pocket which is placed at the extracellular side of the helix bundle that is 
highly conserved among the members of a subfamily [39, 68]. Interestingly, while 
residues defining the orthosteric binding site are well conserved within the different 
GPCR subfamilies, those of the extracellular loops are remarkably diverse within a 
subfamily, providing a good possibility to design selective allosteric antagonist [69]. 
Broadly knowledge of the structure-activity relationships of the different subtypes will 
help designing new selective ligands with various pharmacological profiles that may be 
beneficial for therapeutic intermediation. In this sense, due to the scarcity of 
crystallographic structures available, molecular modeling methods can provide a deeper 
insight into the flexibility and the role that extracellular loops may play in ligand 
recognition [70].  
1.4. Muscarinic receptors antagonists  
  
A receptor antagonist is a type of receptor ligand or drug that does not provoke a 
biological response itself upon binding to a receptor, but blocks or dampens agonist 
mediated responses. Residues important for the binding of ligands have not been defined. 
Sites involved in binding different receptor-selective antagonists are probably quite 
diverse, depending on the antagonist [57]. It is very difficult to identify amino acids that 
interact directly with antagonists and to distinguish such residues from those which, when 
mutated, affect antagonist binding site suggested that a conserved Asn residue in the sixth 
transmembrane segment is very important for the binding of certain subclasses of 
antagonists [62] that in this study tiotropium and N-methylscoplamine are our interest 
antagonist to follow aim of the investigate.  
  
1.4.1. Tiotropium  
Tiotropium is a specific antagonist (long-acting, 24 hour, anti-cholinergic 
bronchodilator)of muscarinic receptors that binds to all receptor subtypes with similar 
affinity (figure 1.5), but it dissociates from the M1 and M3 muscarinic receptors more 
slowly than from the M2 muscarinic receptor. Also it often referred to as an 
antimuscarinic or anti-cholinergic agent. In contrast to ipratropium, tiotropium has 
roughly a tenfold greater affinity for muscarinic receptors, and it dissociates ~100-fold 
more slowly from the M1 and M3 muscarinic receptors, because of the rationale behind 
 the sustained bronchodilation obtained with tiotropium. On tropical application it acts 
mainly on M3 muscarinic receptors [71, 72] located on smooth muscle cells and 
submucosal glands leading to a reduction in smooth muscle contraction and mucus 
secretion, thus producing a bronchodilatory effect. This translates into a prolonged 
duration of action for tiotropium bromide compared with ipratropium bromide, allowing 
once-daily dosing via oral inhalation.  
  
 Formula  C19H22BrNO4S2  
Figure (1.5): structure of tiotropium  
 
Tiotropium is used for maintenance treatment of chronic obstructive pulmonary disease 
(COPD) which includes chronic bronchitis and emphysema [73]. It is not however used 
for acute exacerbations [43]. In chronic obstructive pulmonary disease (COPD) and 
asthma, inflammatory conditions lead to loss of neuronal inhibitory activity mediated by 
M2 on parasympathetic nerves, causing excess acetylcholine reflexes [74] which result 
in airway hyper reactivity and hyper responsiveness mediated by increased acetylcholine 
release and thus excess stimulation of M3. Therefore, potent mAchRs antagonists, 
particularly directed toward the M3 subtype, would be useful as therapeutics in these 
muscarinic acetylcholine receptor mediated disease states [75], mostly through activation 
of the human muscarinic M3 receptor (hM3) subtype [4].  
  
1.4.2. N-Methylscopolamine  
  
N-Methylscopolamine (NMS) is a methylated derivative of scopolamine, and a 
muscarinic antagonist structurally similar to the neurotransmitter acetylcholine. Its 
mechanism of action involves blocking the muscarinic acetylcholine receptors.  
 Methylscopolamine or meth scopolamine, usually provided as the bromide salt (trade 
name Pamine), is an oral medication used along with other medications to treat peptic 
ulcers by reducing stomach acid secretion. With the advent of proton pump inhibitors and 
antihistamine medications it is rarely used for this anymore. It can also be used for 
stomach or intestinal spasms, to reduce salivation and to treat motion sickness. Meth 
scopolamine is also commonly used as a drying agent, to dry up post-nasal drip, in cold, 
irritable bowel syndrome and allergy medications.  
In a recent investigation an optimized rhodopsin-based homology model of the 
muscarinic receptor M1 has been used to dock NMS and other ligands, in a manner 
compatible with the effects of the TM domain alanine mutations on binding affinity. They 
suggest that at the bottom of the binding pocket of the muscarinic M1 receptor, 
mutagenesis and modeling suggest that Trp378 contributes directly to the binding pocket 
for NMS although possibly with different side chain orientations [76] (figure  
1.6)  
As mentioned above, the precise binding of ligands is largely unknown and every ligand 
has its particular binding. At the M3 muscarinic receptor the mutation of tryptophan 6.48 
to phenylalanine reduces NMS affinity [37]. Thus, the aromatic character of Trp378 may 
be key for the binding of NMS. Moreover, molecular modeling studies suggest that the 
side chains of NMS follow distinct vectors within the binding site (Figure 1.5). The 
phenyl ring of the tropic acid side chain of NMS may extend deep into the transmembrane 
domain region toward TM5 [76].  
  
  
  
Figure (1.6): Molecular model of the muscarinic M1receptor binding site docked with N-
methylscoplamine [76].  
  
  
  
  
  
  
  
  
  
  
  
   
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Methods  
  
  
  
  
  
  
  
  
 2.0 Computational chemistry  
  
Computational chemistry concerns the utilization of analytical (data) and theoretical 
methods, mathematical modeling and computational study of biological, chemical and 
behavioral systems. There are two fields of computational chemistry: information 
management and molecular modeling. The former refers to the management and analysis 
of huge amounts of data created by combinatorial chemistry and genomic sequencing. On 
the other hand, molecular modeling consist in the construction of a mathematical model 
that can be used to predict, explain and stimulate the behavior of a molecular system [61, 
77, and 78].  
In general, computational chemistry and molecular modeling can be used indistinctly, 
however it is important to keep in mind that molecular modeling does not always happens 
in a computer or using a computer and on the other hand, computational chemistry is not 
always about constructing models. Indeed, one can use a molecular modeling kit to build 
a physical model that represents molecules and their interactions [61, 77, and 78].  
One the basic principles of medicine chemistry is that biological activity dependents on 
the three dimensional placement of specific functional groups that define a 
pharmacophore. Construction of a pharmacophore can be carried out in a ligand based 
manner, by superposing a set of active molecules and extracting common chemical 
features that are essential for their bioactivity, or in a structure-based manner, by probing 
possible interaction points between the macromolecular target and ligands [59, 60, 79-
81]. Methods used in molecular modeling are related, and are not only restricted to the 
analysis of three dimensional structures. Thus, construction of protein models by 
sequence homology or molecular docking are also some other parts of the model 
construction. In molecular modeling different strategies are used to explore and deduce 
information of a system. Some of the strategies involve computation of the energy of a 
molecular system and energy minimization (calculating local energy minima) [80].  
Some of the constructed molecular models utilize accessible crystallographic data.  
Crystal structures are frequently as close as you can get to ‘reality’, but on the other hand, 
they are models and should be treated with some skepticism. The raised problem comes 
from multiple crystal structures of molecule (s) of interest which are available. In this 
situation, the higher resolution crystal structure is generally preferred. Among the high 
resolution crystal structures, the best one for docking is that one which does not have 
 missing portions, and which is preferably also unencumbered by the presence of a whole 
lot of counterions, stabilizing molecules, and other ligands [82, 83].When there is no 
crystal structure available, other methodologies may be applied like homology modeling 
[84-86]. After construction target protein or complex structure, the bonding of the 
compound of interest can be generated using a docking algorithm.  
2.2. Homology Modeling  
  
As mentioned in the previous section, characterization of a protein sequence is one of the 
most frequent problems in biology this task is usually facilitated by a three dimensional 
(3D) structure of the studied protein [87]. In other words, structure-activity studies require 
a high-quality three dimensional structure of the target receptor. Due to the difficulties 
associated in growing crystals for GPCRs, models of this class of proteins are currently 
constructed by homology modeling. This is an important issue, since homology models 
have application in virtual screening studies, docking experiments (small molecule and 
protein-protein interactions) as well as being used to generate hypotheses about intra- and 
inter-molecular mechanisms [88].  
Homology modeling has become increasingly common and although any methods of 
homology modeling include of four sequential steps:  
I. Template recognition  
II. Alignment of the target sequence and template structure(s)  
III. Model building  
IV. Model verification, which may be used iteratively with steps i-iii.  
Sequence alignment can be used to understand sequence similarity between template and 
target sequences, in particular in loop region that need high amount of alignment in both 
sequence and structure. [89].  
The most probable arrangement of the seven helixes in GPCRs, was derived from 
structural information extracted from a detailed analysis of the sequence.  These 
constraints include:  
1. Each helix must be positioned next to its neighbors in the sequence.  
2. Helices I, IV and V must be most exposed to the lipid surrounding the receptor 
and helix III least exposed.  
 3. Is established from the lengths of the shortest loops.  
4. Is determined by considering: (i) sites of the most conserved residues; (ii) other 
sites where variability is restricted; (iii) sites that accommodate polar residues ;( 
iv) sites of differences in sequence between pairs or Within groups of closely 
related receptors[36].  
2.2. Molecular docking  
  
The aim of molecular docking is to computationally simulate the molecular recognition 
process. The associations between biologically related molecules such as proteins, 
nucleic acids, carbohydrates and lipid play a central role in signal transduction. Thus, the 
relative orientation of two interacting partners may affect the type of signal produced 
(e.g., agonist vs. antagonist). Because docking is helpful for predicting both the strength 
and type of signal produced. The purpose of molecular docking is for access an optimized 
conformation for both the protein and ligand and relative orientation between them, to 
know better the ruling principles whereby protein receptors recognize, interact and 
associate with molecular substrates and inhibitors is of paramount important in drug 
discovery attempts [90]. Protein-ligand docking leads to predict and rank the structures 
come from the dependency between a given ligand and a target protein of known three 
dimensional structure.  
The capability to produce the binding poses is as important as the ability of its scoring 
function to score and rank ligands according to their experimental binding affinities. 
There have been a number of attempts for comparison strength of different docking 
protocols, where the comparison is often categorized into evaluation of the search 
algorithm and the scoring function [90-93]. A disinterested comparison of each effort 
obviously explained that it is very difficult to rank and recognize different optimization 
strategies, particularly with enhanced algorithms complexity. It was necessary to note that 
the implementation of any docking protocol with only depend on the core algorithms, the 
time invested in parameterization and optimization of the methodology.  
There are several molecular docking software such as: Gold, Glide, Auto dock, etc. [9094] 
. In this study two pieces of software’s were used: Genetic optimization for ligand 
docking (GOLD) and molecular operating environment (MOE).  
  
 2.2.1. Genetic optimization for ligand docking (GOLD)  
  
Gold application is based on a genetic search algorithm that allows full ligand flexibility, 
as well as local flexibility for the protein receptor polar hydrogens [90, 91, 95, and 96]. 
Gold scoring function includes the analysis of about 100 different protein complexes and 
provides a 71% success rate in identifying the experimental binding models. However 
systemic problems in ranking have different polar ligands and in ranking general ligands 
in large cavities have been reported [16, 80, 97, and 98].  
Like all docking program GOLD has three main parts:  
1-ligand placement mechanism  
2-search algorithm (conformational search)  
3-scoring function  
The first part of GOLD is the mechanism for placing the ligand in the binding site. GOLD 
ligand assignment is based on fitting points. The program adds fitting points to hydrogen 
binding groups on protein and ligand, and maps acceptor points in the protein and vice 
versa. Moreover, GOLD creates hydrophobic fitting points in the protein cavity onto 
which ligand CH groups are mapped.  
The second part of GOLD software is the search algorithm to explore possible binding 
modes; GOLD applies a genetic algorithm (GA) in which the following parameters are 
modified /optimized:  
• Dihedral of ligand rotatable bonds.  
• Ligand ring geometries (by filliping ring corners )  
• Dihedrals of protein OH groups and NH3 groups  
• The mapping of the fitting points (i.e., the position of the ligand in the binding 
site) [16, 98].  
Lastly a scoring function ranks different binding modes, the Goldscore function is a 
molecular mechanics –like function with four terms:  
GOLD fitness=shb _ext +svdw_ext +shb_int    Eq (2.1)  
Where;  
• Shb_ext is the protein -ligand hydrogen bond score.  
• Svdw_ext is the protein -ligand van der Waals score.  
• Shb_int is the contribution to the fitness due to intramolecular hydrogen bonds 
in the ligand.  
 • Svdw_int is the contribution due to intramolecular strain in the ligand [16, 
98].  
In this study GOLD software was used to perform the main docking calculations, using 
the Goldscore as a scoring function and the parameters chosen includes flipping ring 
corners ,planer and pyramidal nitrogen ,allowing ratable H2O molecules, diverse poses 
during placing and rotating interacting hydrogen bonds .  
2.2.2. Protein and ligand preparation using MOE  
  
MOE1 is a software system designed to support among other things molecular modeling, 
and structure -based -design. Using the SVL (scientific vector language), a scripting and 
application development language of MOE, can be used as a platform with another 
program .In this study MOE was used at the stage of preparation of molecular structures, 
energy minimization, post docking refinement and visualization.  
Molecular system optimization involves preparing the structure to be docked for the 
stimulation .in the case of this study, it included identification of missing residues and 
atoms, energy minimization and protonation states assignment. Unfortunately, most 
macromolecules crystal structure contain little or no hydrogen coordinates data due to 
limited resolution or disorders in the crystal. Explicit hydrogen atoms are required for all 
atoms molecular mechanics, docking and electrostatic calculations. The initial state of the 
hydrogen bond network and ionization state of treatable groups can have a dramatic effect 
on docking results.  
Since the hydrogen data is missing in PDB files most software programs assign default 
protonation states to amino acid, or nucleic acid residues as well as counter ions and other 
solvent, the additional of hydrogen atoms to the macromolecules is a non-trivial task 
.MOE uses Protonate 3D method to do this. The purpose of the Protonate 3D function is 
to assign ionization states and position of hydrogens in macromolecular structure given 
in 3D coordinates (typically from a crystal structure). The main task is to determine;  
• The rotamers of –SH –OH –CH3 and –NH3 groups in Cys, Ser,Tyr,Thr,Met 
and Lys;  
• The ionization states of acids and bases in Arg,Asp,Glu,Lys,His ;  
                                                 
1 http://computing.scs.illinois.edu/sites/default/files/SCS-UIUC-moe-tutorial-dock-05-2011.pdf  
 • The tautomers of imidazoles (His) and carboxile acids (Asp,Glu).  The 
protonation state of metal ligand atoms Cys,His,Asp,Glu,etc ;  The ionization 
state of metals.  
• The element identities in His , terminal amides (Asn,Glu) and sulfonamides; 
 The orientation of each water molecule.  
Afterward the missing residue and atoms added to the receptor structure as well as the 
ligand structures were submitted to an energy minimization calculation .energy 
minimization is necessary to provide a local energy minimum, lower energy states are 
more stable and thus are considered to be the native state of the system. For this study the 
MOE’s MMFF94x force field was used .it should be noted that a good force field is able 
to quantatively describe the ligand and the target individually as well as bound. This 
requires the force field to have outstanding prediction of conformational energies and 
good prediction of molecular geometrics if it is to avoid modeling the wrong 
conformations of ligand or receptor upon binding or providing a poor estimate of 
energetic cost of adapting the detailed conformation required for binding. MMFF94x is 
the best force field for computing behavior of small molecules, protein and nucleic acid 
structures, Furthermore, MMFF94x is particularly distinctive in its performance when 
applied to studies of binding [99].  
The objective of this thesis is to study the muscarinic M3 receptor by molecular dynamics 
simulations therefore we decided use the M3 muscarinic receptor model to develop the 
molecular dynamics simulations.  
Molecular Mechanics (MM) and Molecular dynamics (MD) are related but different. 
Main purpose of MD is modeling of Molecular Dynamics molecular motions, although it 
is applied for optimization. Molecular Mechanics and Molecular Dynamics are usually 
based some classical force fields.  
2.3Molecular dynamics Simulations  
  
Molecular dynamics (MD) simulations is a powerful technique to obtain detailed 
information on the structure and dynamics of macromolecules. Specifically, it provides 
atomic-level insights into variety of systems of increasing size and complexity, including 
the simulations of 7-transmembrane protein embedded in membranes [100].  
Molecular dynamics simulations generate information at the microscopic level, including 
atomic positions and velocities, through microscopic simulations. The conversion of this 
 microscopic information to macroscopic observables such as pressure, energy, heat 
capacities, calculate changes in the binding free energy of a particular drug candidate, or 
to examine the energetics and mechanisms of conformational change, requires statistical 
mechanics. Statistical mechanics is fundamental to the study of biological systems by 
molecular dynamics simulation, which provides the rigorous mathematical expressions 
that relate macroscopic properties to the distribution and motion of the atoms and 
molecules of the N-body system; molecular dynamics simulations provide the means to 
solve the equation of motion of the particles and evaluate these mathematical formulas. 
With molecular dynamics simulations, one can study both thermodynamic properties 
and/or time dependent (kinetic) [101]  
Nowadays MD simulations have the power to gain insight into different kinds of chemical 
reactions at atomic level. Therefore the MD simulation technique has become quite 
powerful in elucidating features of biological macromolecules.   
Examples of commonly used programs for MD simulations biomolecules are AMBER 
[102], CHARMM [103], ENCAD [104] and GROMOS. The major packages have similar 
capabilities in terms of what systems can be studied and the kinds of your molecular 
system, the actual simulation has to be performed and finally the results have to be 
analyzed.  
2.3.1 MD principles  
  
Using MD it is possible to stimulate the time-evolution of a molecular system, which is 
represented classically considering a set of particles defined by their positions and 
momenta.   
Molecular dynamics simulations are based on solving Newton’s second law or the 
equation of motion. Newton’s equation of motion is given by:  
i i iF m a  
Where Fi is the force exerted on particle i, mi is the mass of particle i and ai is the 
acceleration of particle i. From knowledge of the force on each atom it is possible to 
determine the acceleration of each atom in the system. The method is deterministic, once 
the positions and velocities of each atom are known; the state of the system can be 
predicted at any time in the future or past.  
 The force of an atom can also be expressed as the gradient of the potential energy,  
i iF V   
The potential energy is a function of the atomic positions of all the atoms in the system.  
Combining these two equations it yields:   
2
2
i
i
i
d rdV
m
dr dt
   
Where V is the potential energy of the system. Newton’s equation of motion relate the 
derivative of the potential energy to the changes in position as a function of time. Due to 
the complicated nature of this function, it must be solved numerically. Numerous 
numerical algorithms have been developed for integrating the equations of motion such 
as: the Verlet algorithm, Leap-frog algorithm, velocity Verlet or the Beeman´s algorithm.  
2.3.2 Force fields  
  
The accuracy of the energy function directly affects the stability of MD simulations of 
biological macromolecules. For reasons of computational efficiency when dealing with 
large macromolecular systems the energy function has to be simple, and since force 
calculations are needed in MD simulations, the function should also be analytically 
differentiable.   
Force field refers to the functional form and parameter sets to describe the potential 
energy of a system of particles. The basic functional form of a force field encapsulates 
both bonded terms relating to atoms that are linked by covalent bonds, and non-bonded 
terms describing the long-range electrostatic and van der Waals forces. The specific 
decomposition of terms depends on the force field, but a general form for the total energy 
in an additive force field can be written as:   
𝐸𝑡𝑜𝑡𝑎𝑙 =𝐸𝑏𝑜𝑛𝑑𝑒𝑑 +𝐸𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑  
 The intramolecular potential energy is typically represented by harmonic oscillators for 
bond stretching and angle bending, a Fourier series for each torsional angle, and Coulomb 
and Lennard-Jones (LJ) accounting for the interactions between atoms separated by three 
or more bonds. The latter two terms –referred together as non-bonded terms- are 
evaluated between all atom pairs in the system to yield the intermolecular energy. Such 
force fields compute the energy as a sum of terms representing bond elongation, angle 
and dihedral deformation, and non-bonded interactions with the following general form:  
str bend tors LJ Coul
Bonds angles torsions LJ Coulumb
E V V V V V          
Where the first three summations correspond the bonded terms (that include atoms 
connected up to three consecutive bonds) and the last two refer to the non-bonded ones. 
All summations can be easily calculated from the coordinates of the system at a given 
time.  
There are four main force fields in common use for simulation biological 
macromolecules: AMBER [105], CHARMM [103] GROMOS and OPLS [106]  
The all-atom OPLS force field [106] which implemented in GROMACS was used for all 
molecules of the system [107]. OPLS refers to Optimized Potentials for Liquid 
Simulations. This force field have proved to be highly successful in computing liquid 
state thermodynamic properties and more recently in protein and protein-ligand 
modeling. Although non-bonded interactions (charge-charge and van der Waals terms) 
can be obtained from liquid state calculations, Parameters such as stretching, bending and 
torsional terms are generally fit to quantum chemical calculations. So they can be superior 
to many alternatives.  
The components of the systems studied included proteins, lipids, water molecules and 
ions were as follows:  
Protein: a) M3 muscarinic receptor without any ligand; b) M3 muscarinic receptor 
docking with tiotropium; c) M3 muscarinic receptor with N-Methylscopolamine [106].  
Water molecules:  TP3P water is one of the 3 site water models which  are very popular 
for molecular dynamics simulations because of their simplicity and computational 
efficiency [108], and it refers to the 3 -point model which is re-parameterized to improve 
 the energy and density for liquid water, that is why it has been chosen as the water model 
for the simulations in this thesis.  
Lipids: In this study we use POPC lipid and the parameters were taken from references 
[109-111].   
All proteins arranged with the lipid bilayer and the water molecules. After equilibration 
and minimization, molecular dynamic simulation was performed.  
2.3.4 Simulations of the M3 muscarinic acetylcholine receptor  
  
In order to understand the structural features of the M3 receptor three different molecular 
dynamic was performed with the receptor embedded in the lipid bilayer were carried out 
using GROMACS package 4.6 package. Specifically, trajectories of the M3 receptor 
embedded in a bilayer of palmitoyl-oleyl phosphatidylcholine (POPC) were run without 
and with the antagonists N-Methylscopolamine and tiotropium, respectively. The POPC 
bilayer was considered in this study because it has been widely used in MD simulations 
of lipid bilayers and its force field parameters have been carefully calibrated and also 
because they are found  in  liquid-crystalline  phase  at temperature 
condition (300K).  
 
 
  
 
 
 
 
 
Figure (2.1): Lipid structures used in the Molecular Dynamics Simulations.  
  
  
  
  
  
  
  
  
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
Chapter 3: Results and Discussion  
  
  
  
  
  
  
  
     
3. 0 Overview of the modeling carried out in this 
work  
In the present study we carried out a homology modeling study of the M3 muscarinic 
receptor using the crystal structure of the M2 muscarinic receptor as template [112] (entry 
3UON of the Protein Data Bank), by means of the MOE software. For this purpose we 
carried out the alignment of the two sequences in order to identify the helical and loop 
segments of the protein. Prior to be used as a template in homology modeling process, 
the crystal structure of M2 had to be prepared. The raw structure contains an insertion of 
a T4-Lysozyme (T4L) in the third intracellular loop. The main purpose of insertion of 
T4L is to facilitate the growth of diffraction crystals during crystallization purposes [33, 
112]. Thus before proceeding to build a homology model of a target protein, the T4L had 
to be removed.  
After template preparation, an alignment of the template and target sequences was done. 
In accordance with the alignment results, a rough model of the M3 receptor was built 
using MOE software. Through visualization and MOE utilities, the constructed model 
was checked for close contacts and subsequently the backbone dihedral angles were 
projected on the Ramachandran plot.  
Once structure validation was completed, two docking calculation were performed to the 
rough model of M3 muscarinic receptor: docking of antagonists tiotropium and N-
Methylscopolamine (see sections 1.4.1 and 1.4.2).  Both ligands separately were docked 
into the binding pocket of the M3 receptor using the MOE induced fit protocol and the 
GOLD placement algorithms. The results obtained are consistent with those previously 
reported by Martinez et al. for N-Methylscopolamine and Krus et al. for tiotropium [113, 
114] (see figure 3.1 and figure 3.2). Henceforth, two protein-ligand complexes of M3 
muscarinic receptor were available for refinement with molecular dynamic simulations. 
In addition, as for the main objective of this study, a rough model of the protein without 
ligand was also put into refinement processes for comparison purposes.  
As mentioned above, refinement of the structures was carried out using molecular 
dynamics (MD) simulations. For this purpose, three separately MD simulations of the 
models embedded in a lipid bilayer of POPC were performed. Among others, the analysis 
of the trajectories permitted to identify different conformations adopted by the loops and 
the effect of the ligand on the protein structure. Finally, in order to understand the 
 accuracy of the models were compared with the crystal structure of M3 available from 
the protein data bank (entry 4DAJ of the protein data bank).  
3.1. Sequence alignment and homology modeling  
  
The sequences of the human M2 and M3 muscarinic receptor were retrieved from the 
UNIPROT website 2  and the sequence alignment was done using the program 
CLUSTALW 3  (Table 3.1). The alignment parameters included: no gaps on the 
transmembrane helices, a correct alignment of the conserved amino acids of the GPCR 
family according to the figure(3.1) and also, taking into account the range of lengths of 
inter-helical loops observed over the whole receptor family as shown in table(3.1) [36]. 
In addition, the sequence of M3 muscarinic receptor used was modified at the third 
intracellular loop. Both M2 and M3 and other subtypes of muscarinic receptors have a 
long i3, whose portion can be deleted without interfering with the general functions of 
the receptor. Thus, based on the number of i3 residues removed in the M2 muscarinic 
crystal structure, a portion of i3 was excluded and removed from the alignment and 
subsequent homology modeling.  
  
  
Table (3.1): Range of the lengths of inter-helical loops over the whole receptor family 
[32].Intra/extra  
  
  E  I  E  I  E  I  E  I  
Region  N-TER  I-II  I-III  III-IV  IV-V  V-VI  VI-VII  C-TER  
Min size  6  5  13  10  12  12  8  12  
Max size  394  11  22  18  43  420  20  162  
                                                 
2 (http://ww2w.uniprot.org/)  
3 http://www.genome.jp/tools/clustalw/  
  
  
Figure (3.1). Residues that are characteristic for each helix and the distribution of polar residues. 
Positions in each helix are numbered on the left, upwards for segments T, HI, V, VII and 
downwards for segments TI, IV and VI; the intracellular surface of the membrane is at the top of 
the figure. The symbols on the left of the position numbers indicate that a site is occupied by a 
polar residue in a few sequences (+ +) or in > 10% of the sequences (# #). No symbol on the left 
indicates that there is never a polar residue at the site. ('Polar' residues include Asp, Asn, Glu, Gln, 
His,Arg, Lys; all others are regarded as able to face the lipid.) The highly conserved residues in 
each helix are labelled to the right. The percentage occurrence of the labelled residue (or one of 
the labelled pair) in 105 unique sequences is shown to the right of the label [36].  
  
  
  
In the pairwise sequence alignment, M2 and M3 muscarinic receptors were observed to 
exhibits an average of 77% sequence homology on the transmembrane segments (as 
shown in Table 3.2).  Furthermore, best score of sequence identity is found in helix three 
and the lowest in helix 1 (as can be seen in table 3.3).  
  
 
  
Table (3.2): Sequence alignment of M2 and M3  
 
  
  
  
  
  
  
 
 
 
 
  
  
  
  
  
  
  
   
  
Table (3.3): Score of identity residues in helixes   
 
H1M2            VVFIVLVAGSLSLVTIIGNILVM-  
H1M3            VVFIAFLTGILALVTIIGNILVIV                 
****.:::* *:**********:   
Helix1 Aligned. Score: 69.5652  
H2M2            YFLFSLACADLIIGVFSMNLY  
H2M3            YFLLSLACADLIIGVISMNLF  
                ***:***********:****:  
Helix2 Aligned. Score: 85.7143  
H3M2            LWLALDYVVSNASVMNLLIISF  
H3M3            LWLAIDYVASNASVMNLLVISF  
                ****:***.*********:***  
Helix3 Aligned. Score: 86.3636  
H4M2            AGMMIAAAWVLSFILWAPAILFW  
H4M3            AGVMIGLAWVISFVLWAPAILFW  
                **:**. ***:**:*********  
Helix4 Aligned. Score: 78.2609  
H5M2            AVTFGTAIAAFYLPVIIMTVLYW  
H5M3            TITFGTAIAAFYMPVTIMTILYW  
                ::**********:** ***:***  
Helix5 Aligned. Score: 78.2609  
H6M2            ILAILLAFIITWAPYNVMVLI  
H6M3            LSAILLAFIITWTPYNIMVLV  
                : **********:***:***:  
Helix6 Aligned. Score: 76.1905  
H7M2            IGYWLCYINSTINPACYALC  
H7M3            LGYWLCYINSTVNPVCYALC  
                :**********:**.*****  
Helix7 Aligned. Score: 85  
   
Furthermore, during alignment of the two sequences the following considerations were 
taken into account in order to build the model:  
I. Starting and finishing points for each of the 7 helixes  
II. Check that conserved residues align together   
III. Check the position of two cysteine residues of the disulfide bridge  
IV. Alignment of big loops together (small loops are not important as big 
loops) Table 3.4 shows a detailed comparison of the conserved residues and the 
different motifs deduced from the sequence alignment.  
Extracellular loops  
The resulting M3 muscarinic receptor model has similar length and loop morphology as 
that of the template M2 muscarinic receptor. Accordingly, the disulfide bridges observed 
in M2 muscarinic receptor were also conserved in M3 muscarinic receptor. In the target 
receptor these bridges were observed to be between Cys140 of the N-terminus of helix 3 
and Cys220 of the second extracellular loop, and between Cys516 and Cys519 of the third 
extracellular loop including the directly neighbored amino acids were as depicted in the 
M2 muscarinic acetylcholine receptor (see figure (3.2).   
 
Figure (3.2): The two disulfide bridges in the structure of M3 muscarinic receptor between 
Cys140-Cys220 and also Cys516-Cys 519(numbering of residues appear in all the figures shifted 
one residue)  
 
 
  
 Table (3.4): Result position of Conserve Residue of the study  
  
  
 
 
 
 
 
 Intracellular loops  
As observed in the extracellular loops, the intracellular loops of the constructed M3 
muscarinic model were similar to those of the template M2 muscarinic receptor. As seen 
in previous studies [115], a similarity in length and predicted secondary structure was 
observed between M2 and M3 muscarinic receptors. Accordingly, the coordinates of M2 
muscarinic receptor were accepted for the M3 model.   
  
N-terminus/ C-terminus  
The secondary structure of the N-terminus and C- terminus of target M3 muscarinic 
receptor were also similar to the template M2 muscarinic receptor.  
  
  
Figure (3.3): Ramachandran map for human M3 muscarinic receptor showing that 100% of the 
observed dihedral angles are clustered in the sterically allowed regions.  
  
Overall Structure validation  
Once a rough homology model of the M3 receptor was constructed using the constructed 
MOE, the software was used to validate the model. The validation process aims to check 
the stereochemically quality of all protein chains. This is done by visualizing the bonds 
or clashes in between atoms in the model and by computing the values of the backbone 
torsional angles and plotting them in a Ramachandran map to show the distribution of 
angles observed in a single structure. Figure (3.3) shows that all the angles in the 
 constructed M3 muscarinic receptor model are clustered into the allowed stereochemical 
regions of the map.  
3.2. Analysis of the orthosteric binding site  
The orthosteric binding site is the classical binding site where the muscarinic antagonists 
tiotropium or N-Methylscopolamine bind. Previous docking studies of NMethylscopolamine 
bound to the M3 receptors [114] and tiotropium docked to a model of M3 [55] suggested 
different residues involved in recognition (Table 3.5). These residues were used to guide 
the docking of the ligands in the present work.  
Table (3.5): Residues involved in the antagonists binding to M3 muscarinic receptor 
Antagonist  Binding pockets residue  
Tiotropium  Asp147,Tyr148,Trp199,Thr231,Phe239,Tyr506,Asn507,Tyr529,  
Cys532,Tyr533  
NMS  Asp147,Ser151,Asn152,Phe221(ECL2),Ile222(ECL2),Thr234,Ala235, 
Ala238, Trp503, Asn507, Val510, Leu511, Cys532 and Tyr533.  
  
Several induced fit molecular docking calculations of tiotropium and N-methyl 
scopolamine to the constructed model of M3 muscarinic receptor were carried out using 
MOE software and GOLD placement algorithm. The resulted poses were rank ordered by 
binding/docking score and for each of the ligands, the binding pose with the best binding 
score were selected. Figures 3.4 and 3.5 show the residues involved in the binding pocket 
of the M3 muscarinic receptor modeled of tiotropium and N-methyl scopolamine 
respectively.  
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Figure (3.4): Binding pocket of tiotropium. Residues directly involved in binding the 
ligand are: Asp147,Tyr148,Trp199,Thr231,Phe239,Tyr506,Asn507,Tyr529, 
Cys532,Tyr533(numbering of residues appear in all the figures shifted one residue)  
  
 
  
 
Figure (3.5): Bonding pocket of N-Methylscopolamine: Residues directly involved in binding the 
ligand are : Asp147,Ser151,Asn152,Phe221(ECL2),Ile222(ECL2),Thr234,Ala235,   
Ala238, Trp503, Asn507, Val510, Leu511, Cys532 and Tyr533. (Numbering of residues appear 
in all the figures shifted one residue)  
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3.3: Analysis of interactions  
  
According to Kruse et al. [49], in the M3 muscarinic receptor similarly to M2 muscarinic 
receptor, the ligand tiotropium is deeply buried within the 7TM receptor core and is 
covered by a lid comprising three conserved tyrosines (Tyr148, Tyr506 and Tyr529). The 
ligand is almost completely occluded from solvent and engages in extensive hydrophobic 
contacts with the receptor. A pair of hydrogen bonds are formed fromAsn507 to the 
ligand carbonyl and hydroxyl, while Asp147 interacts with the amine group of the ligand.  
Figure 3.6 (a and b) shows the protein-ligand interactions between tiotropium and the M3 
muscarinic receptor as depicted by the best binding score and pose resulted from the 
molecular docking calculations.  
   
  
  
  
  
  
  
  
  
  
  
  
 
 
 
Figure 3.6a: a 2D representation of the interactions between ligand tiotropium and residues in the 
antagonist binding pocket of M3 muscarinic receptors. . (Numbering of residues appear in all the 
figures shifted one residue)  
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Figure 3.6b:  a 3D representation of the interaction between ligand tiotropium and residues in the 
antagonist binding pocket of M3 muscarinic receptors. . (Numbering of residues appear in all the 
figures shifted one residue)  
  
As shown in figure 3.6, the ligand is surrounded by Tyr 148, Tyr506, Tyr529, Asn507 
and Asp147. Among the interacting residues, Asn507 and Asp147 are notably the most 
important ones.  The former forms a hydrogen bond with the carbonyl and hydroxyl 
moieties, and the latter forms an interaction with the amine group, with distance of 4.7 
Å. This distance is long for a hydrogen bond interaction, although it could be mediated 
by a water molecule.  
  
In case of N-Methylscopolamine, several binding studies have identified Asp147 to be 
most important in N-Methylscopolamine binding. This residue is known to interact with 
the ligand quaternary nitrogen. Putatively, Asn507 involved in a polar interaction with 
the ligand, and the homologous hydrophobic residues implicated in the binding of N-
Methylscopolamine at the M3 muscarinic receptor.  
  
Figure 3.7 shows the protein-ligand interactions between N-Methylscopolamine and the 
M3 muscarinic receptor as depicted by the best binding score and pose resulted from the 
molecular docking calculations.  
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Figure 3.7a: a 2D representation of the interaction between ligand N-Methylscopolamine and 
residues in the antagonist binding pocket of M3 muscarinic receptors. . (Numbering of residues 
appear in all the figures shifted one residue)  
  
 
Figure 3.7b:  a 3D representation of the interaction between ligand N-Methylscopolamine and 
residues in the antagonist binding pocket of M3 muscarinic receptors. . (Numbering of residues 
appear in all the figures shifted one residue)  
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3.4. Structural analysis of the refined M3 muscarinic receptor  
  
MD simulations provides detailed information on the fluctuations and conformational 
changes of proteins and nucleic acids.  These methods are now routinely used to 
investigate the structure and dynamics of biological molecules and their complexes, and 
investigate the influence of ligand inside the binding pocket of the receptor.  Three 
molecular dynamic stimulation were computed using the GROMACS 4.6 package [111]. 
One molecular dynamics simulation with the receptor M3 muscarinic receptor without 
any ligand, another one molecular dynamic simulation of tiotropium inside the binding 
pocket of M3 muscarinic receptor and the final simulation was  the ligand N-
Methylscopolamine inside the binding pocket of the M3 muscarinic receptor, in all 
simulations, protein only or protein ligand(s) complex) were embedded in POPC lipid 
bilayer. POPC lipid bilayer, was selected since the force field parameters of this lipid are 
well known.  
3.4.1 Structure equilibration  
  
Equilibration of these systems require long simulation times. The root-mean-square 
deviation (rmsd) of the backbone atoms of the protein can be used to monitor the 
evolution of the system. The time evolution of the root mean square deviation in the 
different simulations performed in the present work, are illustrated in figure (3.8). As can 
be seen for the systems with tiotropium and N-Methylscopolamine, equilibration appears 
after 50 ns, whereas in the simulation without ligand equilibration requires longer times 
of about 350 ns. However, it should be taken into account that much shorter times can be 
observed if only the helical section of the receptors are considered.  
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Figure (3.8): Time evolution of root mean square deviation (rmsd) of the backbone atoms of M3 
receptors. a) Evaluation of M3 with N-Methylscopolamine and tiotropium docked inside; b) 
M3 structure without ligand  
  
Analysis of these plots suggest that for proper analysis, only the stable part of the time 
graph should be considered.  
Table (3.6): Different simulations performed.  
  
Structures  MD Production 
Times  
M3 muscarinic receptor without 
any ligand  
110ns   
M3 muscarinic with tiotropium 
bound to its orthosteric binding 
pocket.  
243ns  
M3  muscarinic  with  N- 
Methylscopolamine bound to its 
orthosteric binding pocket.  
100ns   
  
3.1.2 Rmsf per residue  
  
Rmsf per residue is a suitable tool to describe comparison of deviation among helices 
and intracellular/extracellular loops of M3 receptor that has been modeled.  
  
Rmsf values per residue highlighted less mobility in the backbone region of the M3 
receptor than in the connecting loops (as shown in Figure 3.9). The largest deviations 
correspond mainly to the second and third intra-cellular loops of the protein (deviations 
above 1nm) whereas the smallest ones are shown in the transmembrane region of the 
protein. That fact may be related functional-wise to the assumption that receptor G 
protein/coupling occurs through intracellular loops in all of the muscarinic acetylcholine 
receptors as previously anticipated [116]. It should also be factored that, these largest 
deviations were observed in loops that are long.  
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Figure (3.9): Average root mean square fluctuation (rmsf) of the backbone atoms of each residue 
in three MD simulations performed.  
  
Because residue 262-481 of all structures has been removed, this part can be seen as flat 
part in the graph. Loops of the M3 muscarinic receptor without any ligand were observed 
to have more fluctuations in comparison to M3 muscarinic receptor with ligand 
tiotropium or NMS (complexes).  
  
In drawing comparison between the average structures obtained in three simulations, 
structural deviations are not very large (Figure 3.10) and Table (3.7).The superposition 
of α carbon of the average structure of the refined (after MD simulations) M3 muscarinic 
receptor-ligand complex models, showed similarity to each other and to the crystal 
structure of M3 muscarinic receptor complexes with tiotropium. In contrast, a refined 
model of M3 muscarinic receptor without ligand and more structural deviations. Major 
differences are observed in the third intracellular loop and third extracellular loop. In 
fact, it is also where the M3 structure is more flexible, and have more movement after 
molecular dynamic simulation.  
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Table (3.7): Average RMSD of α carbon of the structure after superposition of three model 
together   
  
Structures  RMSD(Å)  
M3 muscarinic receptor: m3_tio  2.36  
M3 muscarinic receptor: m3_nms  2.16  
M3_tio:m3_nms  2.21  
  
 
Figure (3.10): α carbon superposition of average three models of M3 constructed. As a blow up 
the third intracellular loop shows the largest deviations between the three models.  
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3.1.4. Comparison of constructed models with crystal structure of M3 muscarinic  
receptor  
The most critical assessment of the quality of the models regards direct comparison of the 
refined models (average structures obtained from MD simulations) with the crystal  Structure 
of M3 muscarinic receptor with tiotropium bound to it (entry 4DAJ of the protein data bank). 
The main objective of this comparison was to measure the accuracy of the methodology used 
in this study to predict and construct useful GPCR models. Accordingly, three refined models 
were superimposed with the crystal structure. Overall the models do not show much differences 
with the crystal structure (see Figure 3.11). In fact, superimposition of the Cα of these structures 
shows that deviations are not very large. The closest models are those that included ligand with 
deviations between 1.7 and 2.0 Å, whereas the model produced without ligand deviations are 
much longer (2.5 Å).  
 
Structure  shape  RMSD (Å)  
M3muscuri 
nic 
receptor  
 
  
2.5  
  
  
  
  
M3_tio  
 
  
  
  
2.1  
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M3_nms  
 
  
  
  
  
  
1.7  
  
Figure 3.11: Superposition of average refined models and the crystal structure of M3 
muscarinic receptor (In all of them crystal M3 muscarinic receptor shows in red color)  
A closer inspection of the superimposition of the models and the crystal structure reveal 
some differences. An important issue in the modeling is the accuracy of the predicted 
helices. Table (3.8) shows a comparison of the features of the models with the crystal 
structure regarding the beginning and the ending of the helices.   
Table (3-8): comparison of residues in transmembrane helixes of homology model and crystal 
structure of M3 muscarinic receptor  
  Model  Crystal structure   
Transmembrane Helix  
1  
Trp65-Val 94  Trp65-Val94  
Transmembrane Helix  
2  
Va101-Asn131  Val101-Met130  
Transmembrane Helix  
3  
Asn138-Arg171  Gly137-Arg171  
Transmembrane Helix  
4  
Val186-Val 210  Thr181-Val 210  
Transmembrane Helix  
5  
Pro228-Lys260  Pro228-N/A  
Transmembrane Helix  
6  
Gln490-Cys516  N/A-Cys516  
Transmembrane Helix  
7  
Lys522-Leu558  Lys522-Lys555  
  
55  
  
Analysis of the Table (3.8) reveals that errors are less than one helix turn in most of the 
helices, except in TM4 after the second intracellular loop with more than a helix turn 
difference.  The end of TM5 and the beginning of TM6 connected by the third 
intracellular loop cannot be really compared due to the presence of lysozyme both in the 
crystal structure of M3 muscarinic receptor and in the template used in the homology 
modeling (M2 muscarinic receptor). As mentioned in sections 1.2.2 and 3.1, the third 
intracellular loop is considerably long for all muscarinic receptor subtypes A deletion of 
portion of this loop bears no consequences to the overall function of the GPCR or the 
binding of G- protein to the GPCR. Thus, the deletion of part of the intracellular loop 
(219 residues were deleted during template- target sequence alignment), may have 
contributed to the one helical turn error.   
Comparison of the crystal structures of M2 and M3 reveal that the structures although 
very similar exhibit a few differences as reviewed recently [109]. Present models capture 
most of these features. Thus, for example the position of the ligand deeply buried within 
the transmembrane core is preserved. In agreement with previous models of M3 
muscarinic receptor, Asp147 and Asn507 which are two of the highly conserved residue 
among all biogenic amine receptors, are essential for binding at the M3 muscarinic 
receptor to antagonists. The results show that arginine which is part of the highly 
conserved DRY sequence has got an essential functional role in GPCRs. Also ion pair 
between the ammonium group of acetylcholine and a conserved aspartate residue in the 
TM3 segment (transmembrane segment of helix 3) (Asp147 in M3) plays a key role in 
complex stabilization, which also was identified by Gromada and Hughes [55]. This 
negatively charged residue of TM3 critically interacts with ligands and is indeed a feature 
common to all GPCRs [30]. Inspection of the side chains of M3 surrounding tiotropium, 
the model shows that Asp147 and the amine group of the ligand are at a longer distance 
than expected.   
Another feature captured in our model is a difference is the position of residue L225, a 
phenylalamine (F181) in M2 that creates an extra pocket in M3. However, both structures 
show a bend -not seen in any other GPCRs crystallized so far- that is stabilized by a 
hydrogen bond between Q207 (Q163 in M2) side chain and L204 backbone peptide 
carbonyl. Indeed, mutagenesis of Q207 in M3 impaired both ligand binding and receptor 
activation that is not captured in our model.  
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Conclusions  
  
This study present the effect of the presence of a ligand on the modeling of the structure 
of human M3 receptor. The structure of the M3 muscarinic receptor was constructed by 
homology modeling using the crystal structure of M2 receptor as template, representing 
the inactive form of the receptor. The model was refined using molecular dynamics. In 
the present work we investigated the effect of the ligand on the conformational of protein 
analysis.   
Analysis of the models and their refinement process show that the models constructed 
capture most of the features of the M3 receptor. Moreover, inclusion of a ligand on the 
modeling makes the refinement more robust. Analysis of the root-mean-square deviation 
(rmsd), root-mean-square fluctuations (rmsf) and the equilibration times during the 
trajectory calculation support this conclusion. Interestingly, experimental evidence 
supports the idea that ligands stabilize a receptor as shown on the β2 adrenergic receptor 
after DTT binds to it analyzed by fluorescence spectroscopy [117]. Similarly, based on 
conclusions of several studies, binding of ligand can facilitate and improve on protein 
crystallization processes as shown by the increasing number of structures recently.   
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